Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 46%. Looking ahead, ...

Analyst Jonathan Chang from Leerink Partners reiterated a Buy rating on Zai Lab (ZLAB – Research Report) and keeping the price target at ...

Zai Lab announces $200M share offering amid 47% revenue growth and plans for KarXT submission in China. Multiple companies report changes: Kronos Bio seeks alternatives, Allogene halts trial ...

Limited announced that it has commenced an underwritten public offering of $200M of American depositary shares, ADSs, each ...

Zai Lab and argenx have announced receipt of approval from the National Medical Products Administration (NMPA) of China for ...

Shares of NASDAQ:ZLAB opened at $30.62 on Monday. The business’s 50 day simple moving average is $25.16 and its 200 day ...

Zai Lab Limited (NASDAQ:ZLAB) today announced the promotion of Yajing Chen to Chief Financial Officer (CFO), effective July 7, 2023. Dr. Chen, currently Zai Lab’s Deputy CFO... ByInvesting.com ...

SHANGHAI & CAMBRIDGE, Mass., November 13, 2024--(BUSINESS WIRE)--Zai Lab Limited ("Zai Lab" or the "Company") (NASDAQ: ZLAB; ...

Zai Lab Limited (NASDAQ:ZLAB) today announced that the 2023 National Reimbursement Drug List (NRDL) released by China’s National Healthcare Security Administration (NHSA) has ...

Zai Lab Limited Unsponsored ADR (ZLAB) reported $102.27 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 47.7%. EPS of -$0.42 for the same period ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China’s National Medical Products Administrat ...

Zai Lab (NASDAQ:ZLAB) is scheduled to announce Q3 earnings results on Tuesday, November 12th, before market open. The consensus EPS Estimate is -$0.78 and the consensus Revenue Estimate is $102.24M ...